Literature DB >> 15307210

Osteogenic Protein-1: gene expression and treatment in rat remnant kidney model.

Philip H Dube1, Maria M Almanzar, Kendall S Frazier, William K Jones, Marc F Charette, Ana Paredes.   

Abstract

Osteogenic Protein-1 (OP-1) is a bone morphogen involved in tissue repair and development. We have shown that OP-1 is downregulated during acute ischemic renal injury. Here we report the use of the rat remnant kidney model (RRKM) to evaluate changes in kidney OP-1 expression during chronic injury, and determine if treatment with recombinant human OP-I (rhOP-1) aids in recovery from injury. Sprague-Dawley rats were subjected to kidney decapsulation (Cx) or 5/6 nephrectomy (Nx). Serum for BUN and creatinine and tissue for histology and mRNA analysis were collected at: 2, 10. and 12-14 wks post Nx. We show kidney OP-1 mRNA levels were downregulated at 2 and 12-14 wks post Nx. To determine the effect of rhOP-1 in the RRKM, rhOP-1 (0.25, 2.5 or 25 microg/kg) or vehicle (V) was injected in a second set of rats, 2 weeks after 2/3 left Nx for a total of six doses. Nx rats treated with rhOP-1 showed significantly increased tubular regeneration (increased mitotic figures, polyoid infolding, and tubular epithelialhyperplasia) in a dose dependent manner without changes in glomerular or tubular damage. rhOP-1 stimulates tubular epithelial cell regeneration,early in the repair process in a chronic renal failure model, before significant fibrosis is established.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15307210     DOI: 10.1080/01926230490440925

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  5 in total

Review 1.  Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis.

Authors:  Michael Zeisberg; Raghu Kalluri
Journal:  Am J Physiol Cell Physiol       Date:  2012-12-19       Impact factor: 4.249

2.  Bone morphogenetic protein (BMP)-7 expression is decreased in human hypertensive nephrosclerosis.

Authors:  Carsten P Bramlage; Björn Tampe; Michael Koziolek; Imad Maatouk; Jelena Bevanda; Peter Bramlage; Katharina Ahrens; Katharina Lange; Holger Schmid; Clemens D Cohen; Matthias Kretzler; Gerhard A Müller
Journal:  BMC Nephrol       Date:  2010-11-16       Impact factor: 2.388

3.  CCN2 reduction mediates protective effects of BMP7 treatment in obstructive nephropathy.

Authors:  Lucas L Falke; Jan Willem Leeuwis; Karen M Lyons; Christine L Mummery; Tri Q Nguyen; Roel Goldschmeding
Journal:  J Cell Commun Signal       Date:  2016-10-20       Impact factor: 5.782

4.  A Process for the Design and Development of Novel Bone Morphogenetic Protein-7 (BMP-7) Mimetics With an Example: THR-184.

Authors:  William D Carlson; Peter C Keck; Dattatreyamurty Bosukonda; Frederic Roy Carlson
Journal:  Front Pharmacol       Date:  2022-07-08       Impact factor: 5.988

Review 5.  Role of bone morphogenetic protein-7 in renal fibrosis.

Authors:  Rui Xi Li; Wai Han Yiu; Sydney C W Tang
Journal:  Front Physiol       Date:  2015-04-23       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.